{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T04:50:04Z","timestamp":1794199804457,"version":"4.8.0"},"reference-count":147,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Beta klotho (KLB) is a fundamental component in fibroblast growth factor receptor (FGFR) signaling as it serves as an obligatory coreceptor for the endocrine hormones fibroblast growth factor 19 (FGF19) and fibroblast growth factor 21 (FGF21). Through the development of FGF19- and FGF21 mimetics, KLB has emerged as a promising drug target for treating various metabolic diseases, such as type 2 diabetes (T2D), non-alcoholic fatty liver disease (NAFLD), and cardiovascular disease. While rodent studies have significantly increased our understanding of KLB function, current clinical trials that test the safety and efficacy of KLB-targeting drugs raise many new scientific questions about human KLB biology. Although most KLB-targeting drugs can modulate disease activity in humans, individual patient responses differ substantially. In addition, species-specific differences in KLB tissue distribution may explain why the glucose-lowering effects that were observed in preclinical studies are not fully replicated in clinical trials. Besides, the long-term efficacy of KLB-targeting drugs might be limited by various pathophysiological conditions known to reduce the expression of KLB. Moreover, FGF19\/FGF21 administration in humans is also associated with gastrointestinal side effects, which are currently unexplained. A better understanding of human KLB biology could help to improve the efficacy and safety of existing or novel KLB\/FGFR-targeting drugs. In this review, we provide a comprehensive overview of the current understanding of KLB biology, including genetic variants and their phenotypic associations, transcriptional regulation, protein structure, tissue distribution, subcellular localization, and function. In addition, we will highlight recent developments regarding the safety and efficacy of KLB-targeting drugs in clinical trials. These insights may direct the development and testing of existing and future KLB-targeting drugs.<\/jats:p>","DOI":"10.3389\/fendo.2023.1150222","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T01:36:46Z","timestamp":1684201006000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":64,"title":["Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho"],"prefix":"10.3389","volume":"14","author":[{"given":"Alexandra S.","family":"Aaldijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristy R. C.","family":"Verzijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W.","family":"Jonker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dicky","family":"Struik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41581-018-0078-3","article-title":"The klotho proteins in health and disease","volume":"15","author":"Kuro-o","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/36285","article-title":"Mutation of the mouse klotho gene leads to a syndrome resembling ageing","volume":"390","author":"Kuro-o","year":"1997","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/01.mnh.0000232885.81142.83","article-title":"Regulation of fibroblast growth factor-23 signaling by klotho","volume":"15","author":"Kurosu","year":"2006","journal-title":"J Biol Chem"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.2007.00308.x","article-title":"Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease","volume":"20","author":"Stubbs","year":"2007","journal-title":"Semin Dial"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0925-4773(00)00439-1","article-title":"Molecular cloning and expression analyses of mouse \u03b2klotho, which encodes a novel klotho family protein","volume":"98","author":"Ito","year":"2000","journal-title":"Mech Dev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI23076","article-title":"Impaired negative feedback suppression of bile acid synthesis in mice lacking \u03b2Klotho","volume":"115","author":"Ito","year":"2005","journal-title":"J Clin Invest"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.20.15482","article-title":"Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4","volume":"275","author":"Yu","year":"2000","journal-title":"J Biol Chem"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0701600104","article-title":"\u03b2Klotho is required for metabolic activity of fibroblast growth factor 21","volume":"104","author":"Ogawa","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C700130200","article-title":"Co-Receptor requirements for fibroblast growth factor-19 signaling","volume":"282","author":"Wu","year":"2007","journal-title":"J Biol Chem"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.tig.2004.08.007","article-title":"Evolution of the fgf and fgfr gene families. vol. 20","volume":"20","author":"Itoh","year":"2004","journal-title":"Trends Genet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101152","article-title":"FGF19 and FGF21: in NASH we trust. vol. 46","volume":"46","author":"Talukdar","year":"2021","journal-title":"Mol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/wdev.176","article-title":"The fibroblast growth factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-0532","article-title":"Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis","volume":"150","author":"Badman","year":"2009","journal-title":"Endocrinology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000599","article-title":"Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application","volume":"30","author":"Struik","year":"2019","journal-title":"Curr Opin Lipidol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2015.00193","article-title":"Fibroblast growth factor signaling in metabolic regulation","volume":"6","author":"Nies","year":"2016","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03205-y","article-title":"Sequencing of 53,831 diverse genomes from the NHLBI TOPMed program","volume":"590","author":"Taliun","year":"2021","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.02.063","article-title":"A klotho\u03b2 variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea","volume":"140","author":"Wong","year":"2011","journal-title":"Gastroenterology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.10.011","article-title":"\u03b2-klotho gene variation is associated with liver damage in children with NAFLD","volume":"72","author":"Dongiovanni","year":"2020","journal-title":"J Hepatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103249","article-title":"KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation","volume":"65","author":"Panera","year":"2021","journal-title":"EBioMedicine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201607376","article-title":"KLB, encodhypogonadism is mutated in patients with congenital hypogonadotropic hypogonadism","volume":"9","author":"Xu","year":"2017","journal-title":"EMBO Mol Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"bvaa139","DOI":"10.1210\/jendso\/bvaa138","article-title":"Digenic variants in the FGF21 signaling pathway associated with severe insulin resistance and pseudoacromegaly","volume":"4","author":"Stone","year":"2020","journal-title":"J Endocr Soc"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00322.2009","article-title":"The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance","volume":"298","author":"Schreuder","year":"2010","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2022.2127408","article-title":"Role of fibroblast growth factor 19 in the pathogenesis of nonalcoholic fatty liver disease","volume":"16","author":"Chrysavgis","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1611243113","article-title":"KLB is associated with alcohol drinking, and its gene product \u03b2-klotho is necessary for FGF21 regulation of alcohol preference","volume":"113","author":"Schumann","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2017.08.004","article-title":"Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury","volume":"6","author":"Desai","year":"2017","journal-title":"Mol Metab"},{"key":"B28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.molmet.2018.03.010","article-title":"FGF21, a liver hormone that inhibits alcohol intake in mice, increases in human circulation after acute alcohol ingestion and sustained binge drinking at Oktoberfest","volume":"11","author":"S\u00f8berg","year":"2018","journal-title":"Mol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.04.001","article-title":"The hormone FGF21 stimulates water drinking in response to ketogenic diet and alcohol","volume":"27","author":"Song","year":"2018","journal-title":"Cell Metab"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2021.12.024","article-title":"FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit","volume-title":"Cell Metab","author":"Flippo","year":"2022"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.02.001","article-title":"A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cell Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.02.005","article-title":"FGF21 counteracts alcohol intoxication by activating the noradrenergic nervous system","volume":"35","author":"Choi","year":"2023","journal-title":"Cell Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2208844119","article-title":"FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma","volume":"119","author":"Tao","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00270.2020","article-title":"Levels of \u03b2-klotho determine the thermogenic responsiveness of adipose tissues: involvement of the autocrine action of FGF21","volume":"320","author":"Moure","year":"2021","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13073-019-0690-2","article-title":"Recommendations for application of the functional evidence PS3\/BS3 criterion using the ACMG\/AMP sequence variant interpretation framework","volume":"12","author":"Brnich","year":"2019","journal-title":"Genome Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2337\/db10-0193","article-title":"Obesity is a fibroblast growth factor 21 (FGF21)-resistant state","volume":"59","author":"Fisher","year":"2010","journal-title":"Diabetes"},{"key":"B37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1210\/en.2010-1262","article-title":"Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance","volume":"153","author":"Hale","year":"2012","journal-title":"Endocrinology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1205951109","article-title":"Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor \u03b2-klotho","volume":"109","author":"Fu","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1210\/en.2012-1193","article-title":"TNF-\u03b1 represses \u03b2-klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway","volume":"153","author":"D\u00edaz-Delf\u00edn","year":"2012","journal-title":"Endocrinology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0645","article-title":"High glucose represses \u03b2-klotho expression and impairs fibroblast growth factor 21 action in mouse pancreatic islets: involvement of peroxisome proliferator-activated receptor \u03b3 signaling","volume":"62","author":"So","year":"2013","journal-title":"Diabetes"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.79","article-title":"Increased fibroblast growth factor 21 expression in high-fat diet-sensitive non-human primates (Macaca mulatta)","volume":"38","author":"Nygaard","year":"2014","journal-title":"Int J Obes"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2015.02.104","article-title":"Endoplasmic reticulum stress induces up-regulation of hepatic \u03b2-klotho expression through ATF4 signaling pathway","volume":"459","author":"Dong","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"B43","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1152\/ajpendo.00356.2015","article-title":"1\u03b2 inhibits \u03b2-klotho expression and FGF19 signaling in hepatocytes","volume":"310","author":"Zhao","year":"2016","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2014.76","article-title":"Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients","volume":"39","author":"Gallego-Escuredo","year":"2015","journal-title":"Int J Obes"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygcen.2015.03.009","article-title":"Plasma FGF21 concentrations, adipose fibroblast growth factor receptor-1 and b-klotho expression decrease with fasting in northern elephant seals","volume":"216","author":"Suzuki","year":"2015","journal-title":"Gen Comp Endocrinol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2017.03.009","article-title":"FGF21 resistance is not mediated by downregulation of beta-klotho expression in white adipose tissue","volume":"6","author":"Markan","year":"2017","journal-title":". Mol Metab"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.5009\/gnl17443","article-title":"Expression of fibroblast growth factor 21 and \u03b2-klotho regulates hepatic fibrosis through the nuclear factor-\u03baB and c-jun n-terminal kinase pathways","volume":"12","author":"Lee","year":"2018","journal-title":"Gut Liver"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-18-0002","article-title":"Fasting decreases plasma FGF21 in obese subjects and the expression of FGF21 receptors in adipose tissue in both lean and obese subjects","volume":"239","author":"Nygaard","year":"2018","journal-title":"J Endocrinol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41387-020-0112-y","article-title":"The expression signatures in liver and adipose tissue from obese G\u00f6ttingen Minipigs reveal a predisposition for healthy fat accumulation","volume":"10","author":"Cirera","year":"2020","journal-title":"Nutr Diabetes"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2016.58928","article-title":"Obesity and inflammation: the linking mechanism and the complications","volume":"13","author":"Ellulu","year":"2017","journal-title":"Arch Med Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3804","article-title":"The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease","volume":"21","author":"Youm","year":"2015","journal-title":"Nat Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.719120","article-title":"The nuclear receptor rev-erb\u03b1 regulates adipose tissue-specific FGF21 signaling","volume":"291","author":"Jager","year":"2016","journal-title":"J Biol Chem"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2013.05.005","article-title":"Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones","volume":"2","author":"Adams","year":"2013","journal-title":"Mol Metab"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25609","article-title":"Genomic analysis of hepatic farnesoid X receptor binding sites reveals altered binding in obesity and direct gene repression by farnesoid X receptor in mice","volume":"56","author":"Lee","year":"2012","journal-title":"Hepatology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1210\/me.2015-1226","article-title":"FXR primes the liver for intestinal FGF15 signaling by transient induction of \u03b2-klotho","volume":"30","author":"Fu","year":"2016","journal-title":"Mol Endocrinol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/bs.vh.2016.02.002","article-title":"MicroRNA-34a and impaired FGF19\/21 signaling in obesity","volume":"101","author":"Fu","year":"2016","journal-title":"Vitamins Hormones"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023937","article-title":"Circulating microRNAs in patients with chronic hepatitis c and non-alcoholic fatty liver disease","volume":"6","author":"Cermelli","year":"2011","journal-title":"PloS One"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-010-0226-0","article-title":"Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study","volume":"48","author":"Kong","year":"2011","journal-title":"Acta Diabetol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"289","DOI":"10.12688\/f1000research.14117.1","article-title":"Defining \u201cFGF21 resistance\u201d during obesity: controversy, criteria and unresolved questions","volume":"7","author":"Markan","year":"2018","journal-title":"F1000Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1210\/en.2017-00056","article-title":"Letter to the editor: parameters, characteristics, and criteria for defining the term \u201cfGF21 resistance.\u201d","volume":"158","author":"Tanajak","year":"2017","journal-title":"Endocrinology"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1210\/en.2015-1722","article-title":"Overexpression of \u03b2-klotho in adipose tissue sensitizes male mice to endogenous FGF21 and provides protection from diet-induced obesity","volume":"157","author":"Samms","year":"2016","journal-title":"Endocrinology"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.4161\/adip.29674","article-title":"Characterization of cre recombinase models for the study of adipose tissue","volume":"3","author":"Jeffery","year":"2014","journal-title":"Adipocyte"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nature25010","article-title":"Structures of \u03b2-klotho reveal a zip code-like mechanism for endocrine FGF signaling","volume":"553","author":"Lee","year":"2018","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1822055116","article-title":"Structures of ligand-occupied \u03b2-klotho complexes reveal a molecular mechanism underlying endocrine FGF specificity and activity","volume":"116","author":"Kuzina","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23708","article-title":"Glycosylation of fibroblast growth factor receptor 4 is a key regulator of fibroblast growth factor 19-mediated down-regulation of cytochrome P450 7A1","volume":"52","author":"Triantis","year":"2010","journal-title":"Hepatology"},{"key":"B66","doi-asserted-by":"publisher","first-page":"11045","DOI":"10.1038\/s41598-018-29396-5","article-title":"A systematic dissection of sequence elements determining \u03b2-klotho and FGF interaction and signaling","volume":"8","author":"Shi","year":"2018","journal-title":"Sci Rep"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2012.08.002","article-title":"\u03b2Kslotho is required for fibroblast growth factor 21 effects on growth and metabolism","volume":"16","author":"Ding","year":"2012","journal-title":"Cell Metab"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/cne.24668","article-title":"The central fibroblast growth factor receptor\/beta klotho system: comprehensive mapping in mus musculus and comparisons to nonhuman primate and human samples using an automated in situ hybridization platform","volume":"527","author":"Hultman","year":"2019","journal-title":"J Comp Neurol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1210\/me.2010-0142","article-title":"Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse","volume":"24","author":"Tacer","year":"2010","journal-title":"Mol Endocrinol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24702","article-title":"The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract","volume":"55","author":"Zweers","year":"2012","journal-title":"Hepatology"},{"key":"B72","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1152\/ajpgi.90343.2008","article-title":"\u03b2-klotho and FGF-15\/19 inhibit the apical sodium-dependent bile acid transporter in enterocytes and cholangiocytes","volume":"295","author":"Sinha","year":"2008","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"5171945","DOI":"10.1155\/2018\/5171945","article-title":"The biological role of klotho protein in the development of cardiovascular diseases","volume":"2018","author":"Olejnik","year":"2018","journal-title":"BioMed Res Int"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2017.3140","article-title":"Fibroblast growth factor 21 protects rat cardiomyocytes from endoplasmic reticulum stress by promoting the fibroblast growth factor receptor 1-extracellular signal-regulated kinase 1\/2 signaling pathway","volume":"40","author":"Liang","year":"2017","journal-title":"Int J Mol Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/srep02767","article-title":"Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue","volume":"3","author":"Liu","year":"2013","journal-title":"Sci Rep"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2018.02.109","article-title":"Autophagic control of cardiac steatosis through FGF21 in obesity-associated cardiomyopathy","volume":"260","author":"Rup\u00e9rez","year":"2018","journal-title":"Int J Cardiol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/cvr\/cvu263","article-title":"Fibroblast growth factor 21 protects the heart from oxidative stress","volume":"106","author":"Planavila","year":"2015","journal-title":"Cardiovasc Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3249","article-title":"FGF21 regulates metabolism and circadian behavior by acting on the nervous system","volume":"19","author":"Bookout","year":"2013","journal-title":"Nat Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2014.07.012","article-title":"FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss","volume":"20","author":"Owen","year":"2014","journal-title":"Cell Metab"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/cne.25306","article-title":"Spatial distribution of beta-klotho mRNA in the mouse hypothalamus, hippocampal region, subiculum, and amygdala","volume":"530","author":"Bono","year":"2022","journal-title":"J Comp Neurol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1074\/mcp.M113.035600","article-title":"Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics","volume":"13","author":"Fagerberg","year":"2014","journal-title":"Mol Cell Proteomics"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abh2169","article-title":"A single\u2013cell type transcriptomics map of human tissues","volume":"7","author":"Karlsson","year":"2021","journal-title":"Sci Adv"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X19878889","article-title":"Robust RBM3 and \u03b2-klotho expression in developing neurons in the human brain","volume":"39","author":"Jackson","year":"2019","journal-title":"J Cereb Blood Flow Metab"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2017.09.005","article-title":"FGF19, FGF21, and an FGFR1\/\u03b2-Klotho-Activating antibody act on the nervous system to regulate body weight and glycemia","volume":"26","author":"Lan","year":"2017","journal-title":"Cell Metab"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00182.2018","article-title":"\u03b2-klotho deficiency shifts the gut-liver bile acid axis and induces hepatic alterations in mice","volume":"315","author":"Somm","year":"2018","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M704244200","article-title":"Liver-specific activities of FGF19 require klotho beta","volume":"282","author":"Lin","year":"2007","journal-title":"J Biol Chem"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2008.289","article-title":"FXR: a metabolic regulator and cell protector","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1096\/fj.15-274449","article-title":"Hepatocyte \u03b2-klotho regulates lipid homeostasis but not body weight in mice","volume":"30","author":"Kobayashi","year":"2016","journal-title":"FASEB J"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0913986107","article-title":"Relevant use of klotho in FGF19 subfamily signaling system in vivo","volume":"107","author":"Tomiyama","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21022","article-title":"\u03b2Klotho: a new kid on the bile acid biosynthesis block","volume":"43","author":"Arrese","year":"2006","journal-title":"Hepatology"},{"key":"B91","doi-asserted-by":"publisher","first-page":"247ra100","DOI":"10.1126\/scitranslmed.3009098","article-title":"A nontumorigenic variant of FGF19 treats cholestatic liver disease","volume":"6","author":"Luo","year":"2014","journal-title":"Sci Transl Med"},{"key":"B92","unstructured":"KLB protein summary"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2013.12.003","article-title":"Inventing new medicines: the FGF21 story","volume":"3","author":"Kharitonenkov","year":"2014","journal-title":"Mol Metab"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049977","article-title":"FGF21 requires \u03b2klotho to act In Vivo","volume":"104","author":"Adams","year":"2012","journal-title":"PLoS One"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2013.04.005","article-title":"Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice","volume":"17","author":"Lin","year":"2013","journal-title":"Cell Metab"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2013.03.019","article-title":"An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice","volume":"17","author":"Holland","year":"2013","journal-title":"Cell Metab"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2017.03.005","article-title":"FGF21 regulates metabolism through adipose-dependent and -independent mechanisms","volume":"25","author":"BonDurant","year":"2017","journal-title":"Cell Metab"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040164","article-title":"FGF21 promotes metabolic homeostasis via white adipose and leptin in mice","volume":"7","author":"V\u00e9niant","year":"2012","journal-title":"PloS One"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.601349","article-title":"FGF19 and FGF21 for the treatment of NASH\u2013two sides of the same coin? differential and overlapping effects of FGF19 and FGF21 from mice to human","author":"Henriksson","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M704165200","article-title":"Tissue-specific expression of \u03b2klotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21","volume":"282","author":"Kurosu","year":"2007","journal-title":"J Biol Chem"},{"key":"B101","author":"Mor\u00f3n-Ros","year":""},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16448","article-title":"FGF19 protects skeletal muscle against obesity-induced muscle atrophy, metabolic derangement and abnormal irisin levels via the AMPK\/SIRT-1\/PGC-\u03b1 pathway","volume":"25","author":"Guo","year":"2021","journal-title":"J Cell Mol Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1101\/gad.177857.111","article-title":"FGF21 regulates PGC-1\u03b1 and browning of white adipose tissues in adaptive thermogenesis","volume":"26","author":"Fisher","year":"2012","journal-title":"Genes Dev"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2007.10.007","article-title":"The fasting polypeptide FGF21 can enter brain from blood","volume":"28","author":"Hsuchou","year":"2007","journal-title":"Peptides"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.2337\/db09-1878","article-title":"Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats","volume":"59","author":"Sarruf","year":"2010","journal-title":"Diabetes"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3250","article-title":"FGF21 contributes to neuroendocrine control of female reproduction","volume":"19","author":"Owen","year":"2013","journal-title":"Nat Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201708180","article-title":"\u03b2-klotho sustains postnatal gn RH biology and spins the thread of puberty","volume":"9","author":"Misrahi","year":"2017","journal-title":"EMBO Mol Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.05.022","article-title":"FGF21 signals protein status to the brain and adaptively regulates food choice and metabolism","author":"Hill","year":"2019","journal-title":"Cell Rep"},{"key":"B109","doi-asserted-by":"publisher","first-page":"19521","DOI":"10.1038\/s41598-020-76593-2","article-title":"FGF21 signaling in glutamatergic neurons is required for weight loss associated with dietary protein dilution","volume":"10","author":"Flippo","year":"2020","journal-title":"Sci Rep"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2021.12.024","article-title":"FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit","volume":"34","author":"Flippo","year":"2022","journal-title":"Cell Metab"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101564","article-title":"Pharmacological FGF21 signals to glutamatergic neurons to enhance leptin action and lower body weight during obesity","volume":"64","author":"Claflin","year":"2022","journal-title":"Mol Metab"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.12.004","article-title":"FGF21 is an exocrine pancreas secretagogue","volume":"25","author":"Coate","year":"2017","journal-title":"Cell Metab"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J Clin Invest"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-0221","article-title":"Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity","volume":"150","author":"Berglund","year":"2009","journal-title":"Endocrinology"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.2337\/db05-1435","article-title":"Fibroblast growth factor-21 improves pancreatic \u03b2-cell function and survival by activation of extracellular signal-regulated kinase 1\/2 and akt signaling pathways","volume":"55","author":"Wente","year":"2006","journal-title":"Diabetes"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-022-00572-2","article-title":"\u03b2-klotho promotes glycolysis and glucose-stimulated insulin secretion via GP130","volume":"4","author":"Geng","year":"2022","journal-title":"Nat Metab"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104181","article-title":"Intestinal epithelial \u03b2 klotho is a critical protective factor in alcohol-induced intestinal barrier dysfunction and liver injury","volume":"82","author":"Hou","year":"2022","journal-title":"EBioMedicine"},{"key":"B118","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.freeradbiomed.2022.12.087","article-title":"Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice","volume":"195","author":"Lin","year":"2023","journal-title":"Free Radic Biol Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-17-0727","article-title":"FGF21 acts as a negative regulator of bile acid synthesis","volume":"237","author":"Chen","year":"2018","journal-title":"J Endocrinol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/srep13717","article-title":"Fibroblast growth factor 21 in breast milk controls neonatal intestine function","volume":"5","author":"Gavald\u00e0-Navarro","year":"2015","journal-title":"Sci Rep"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1108","article-title":"Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice","volume":"1","author":"Zhou","year":"2017","journal-title":"Hepatol Commun"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.2337\/db18-1305","article-title":"FGF19 analog as a surgical factor mimetic that contributes to metabolic effects beyond glucose homeostasis","volume":"68","author":"DePaoli","year":"2019","journal-title":"Diabetes"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes","volume":"18","author":"Gaich","year":"2013","journal-title":"Cell Metab"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13023","article-title":"Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates","volume":"19","author":"Kim","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22344","article-title":"Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study","volume":"27","author":"Charles","year":"2019","journal-title":"Obesity"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2021.106335","article-title":"The FALCON program: two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis","volume":"104","author":"Abdelmalek","year":"2021","journal-title":"Contemp Clin Trials"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"293","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"B129","doi-asserted-by":"publisher","first-page":"100057","DOI":"10.1016\/j.xcrm.2020.100057","article-title":"AKR-001, an fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism in type 2 diabetes patients","volume":"1","author":"Kaufman","year":"2020","journal-title":"Cell Rep Med"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32742","article-title":"Fibroblast growth factor receptor 1\/Klotho\u03b2 agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: a phase 1b randomized trial","author":"Wong","year":"2022","journal-title":"Hepatology"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.2337\/db19-140-LB","article-title":"NGM313, a novel activator of betaklotho\/ FGFR1c, improves insulin resistance and reduces hepatic fat in obese, nondiabetic subjects [abstract 140-LB]","volume":"68","author":"DePaoli","year":"2019","journal-title":"Diabetes"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-021-09661-1","article-title":"Beta-klotho in type 2 diabetes mellitus: from pathophysiology to therapeutic strategies","volume":"22","author":"Hua","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30590","article-title":"NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis","volume":"71","author":"Harrison","year":"2019","journal-title":"Hepatology"},{"key":"B136","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2018.11.032","article-title":"Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis","volume-title":"J Hepatol","author":"Rinella","year":"2019"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J Hepatol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1209","article-title":"NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol Commun"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058575","article-title":"Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319","volume":"8","author":"Kharitonenkov","year":"2013","journal-title":"PloS One"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065763","article-title":"LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys","volume":"8","author":"Adams","year":"2013","journal-title":"PloS One"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1210\/en.2016-1917","article-title":"A novel fc-FGF21 with improved resistance to proteolysis, increased affinity toward \u03b2-klotho, and enhanced efficacy in mice and cynomolgus monkeys","volume":"158","author":"Stanislaus","year":"2017","journal-title":"Endocrinology"},{"key":"B142","doi-asserted-by":"publisher","first-page":"162ra153","DOI":"10.1126\/scitranslmed.3004690","article-title":"Treating diabetes and obesity with an FGF21-mimetic antibody activating the \u03b2Klotho\/FGFR1c receptor complex","volume":"4","author":"Foltz","year":"2012","journal-title":"Sci Transl Med"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061432","article-title":"FGF21 can be mimicked in vitro and in vivo by a novel anti-FGFR1c\/\u03b2-Klotho bispecific protein","volume":"8","author":"Smith","year":"2013","journal-title":"PloS One"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.05.028","article-title":"Sustained brown fat stimulation and insulin sensitization by a humanized bispecific antibody agonist for fibroblast growth factor receptor 1\/\u03b2Klotho complex","volume":"2","author":"Kolumam","year":"2015","journal-title":"EBioMedicine"},{"key":"B145","author":"Chen","year":""},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2012073117","article-title":"Antibody-mediated activation of the FGFR1\/Klotho\u03b2 complex corrects metabolic dysfunction and alters food preference in obese humans","volume":"117","author":"Baruch","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.001752","article-title":"A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity","volume":"293","author":"Shi","year":"2018","journal-title":"J Biol Chem"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1150222\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T01:36:51Z","timestamp":1684201011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1150222\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":147,"alternative-id":["10.3389\/fendo.2023.1150222"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1150222","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,16]]},"article-number":"1150222"}}